CRISPR Therapeutics' Shares Slump, but Gene-Editing Pipelines Promise Boost
CRISPR Therapeutics (CRSP 1.66%), a mid-cap biotech, has seen its shares slump over 60% from their 2021 peak. Despite the setback, the company's gene-editing therapies hold promise, with two in vivo medicines, CTX310 and CTX320, administered via intravenous infusions, poised to boost commercial viability beyond its current approved product, Casgevy.
CRISPR Therapeutics' stock could soar if it makes strong clinical and regulatory progress with its pipeline candidates. CTX310, the leading candidate, targets LDL cholesterol and triglycerides, while CTX320 focuses on lipoprotein(a), a risk factor for heart attacks and strokes with limited treatment options. Both therapies are administered via intravenous infusions, making them more commercially viable than Casgevy, which requires a spinal injection.
Investing in CRISPR Therapeutics should be considered a small position in a well-diversified portfolio designed for long-term growth. While buying ETFs that track major indexes is a low-risk strategy, picking individual stocks like CRISPR Therapeutics can potentially yield superior gains. However, it's essential to note that CRISPR Therapeutics carries a higher level of risk due to potential clinical setbacks and competition.
CRISPR Therapeutics aims to advance its gene-editing therapies through clinical trials and regulatory approvals in the coming years. If successful, shareholders such as institutional investors, biotech-focused funds, and early equity holders stand to benefit. Becoming a millionaire through stock investing requires patience, discipline, and informed investment choices, and CRISPR Therapeutics' potential upside makes it an intriguing long-term prospect.
